584 related articles for article (PubMed ID: 27305518)
41. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
[TBL] [Abstract][Full Text] [Related]
42. Comparison of Simulated Outcomes Between Stool- and Blood-Based Colorectal Cancer Screening Tests.
Fendrick AM; Vahdat V; Chen JV; Lieberman D; Limburg PJ; Ozbay AB; Kisiel JB
Popul Health Manag; 2023 Aug; 26(4):239-245. PubMed ID: 37466476
[TBL] [Abstract][Full Text] [Related]
43. Optimal Strategies for Colorectal Cancer Screening.
Jain S; Maque J; Galoosian A; Osuna-Garcia A; May FP
Curr Treat Options Oncol; 2022 Apr; 23(4):474-493. PubMed ID: 35316477
[TBL] [Abstract][Full Text] [Related]
44. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer.
Rex DK; Boland CR; Dominitz JA; Giardiello FM; Johnson DA; Kaltenbach T; Levin TR; Lieberman D; Robertson DJ
Am J Gastroenterol; 2017 Jul; 112(7):1016-1030. PubMed ID: 28555630
[TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
46. Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With a Blood Test That Meets the Centers for Medicare & Medicaid Services Coverage Decision.
van den Puttelaar R; Nascimento de Lima P; Knudsen AB; Rutter CM; Kuntz KM; de Jonge L; Escudero FA; Lieberman D; Zauber AG; Hahn AI; Inadomi JM; Lansdorp-Vogelaar I
Gastroenterology; 2024 Jul; 167(2):368-377. PubMed ID: 38552671
[TBL] [Abstract][Full Text] [Related]
47. Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening: A Microsimulation Model.
Meester RG; Doubeni CA; Lansdorp-Vogelaar I; Jensen CD; van der Meulen MP; Levin TR; Quinn VP; Schottinger JE; Zauber AG; Corley DA; van Ballegooijen M
JAMA; 2015 Jun; 313(23):2349-58. PubMed ID: 26080339
[TBL] [Abstract][Full Text] [Related]
48. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mallant-Hent RC; Lansdorp-Vogelaar I; Bossuyt PMM; Kuipers EJ; Dekker E; Spaander MCW
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):667-675.e1. PubMed ID: 31419575
[TBL] [Abstract][Full Text] [Related]
49. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.
; Davidson KW; Barry MJ; Mangione CM; Cabana M; Caughey AB; Davis EM; Donahue KE; Doubeni CA; Krist AH; Kubik M; Li L; Ogedegbe G; Owens DK; Pbert L; Silverstein M; Stevermer J; Tseng CW; Wong JB
JAMA; 2021 May; 325(19):1965-1977. PubMed ID: 34003218
[TBL] [Abstract][Full Text] [Related]
50. Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening.
Goede SL; Rabeneck L; van Ballegooijen M; Zauber AG; Paszat LF; Hoch JS; Yong JH; Kroep S; Tinmouth J; Lansdorp-Vogelaar I
PLoS One; 2017; 12(3):e0172864. PubMed ID: 28296927
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries.
Naber SK; Knudsen AB; Zauber AG; Rutter CM; Fischer SE; Pabiniak CJ; Soto B; Kuntz KM; Lansdorp-Vogelaar I
PLoS One; 2019; 14(9):e0220234. PubMed ID: 31483796
[TBL] [Abstract][Full Text] [Related]
52. Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model.
Fisher DA; Saoud L; Finney Rutten LJ; Ozbay AB; Brooks D; Limburg PJ
Curr Med Res Opin; 2021 Jun; 37(6):1005-1010. PubMed ID: 33769894
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force.
Meza R; Jeon J; Toumazis I; Ten Haaf K; Cao P; Bastani M; Han SS; Blom EF; Jonas DE; Feuer EJ; Plevritis SK; de Koning HJ; Kong CY
JAMA; 2021 Mar; 325(10):988-997. PubMed ID: 33687469
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
Sonnenberg A; Delcò F; Inadomi JM
Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
[TBL] [Abstract][Full Text] [Related]
55. Colorectal Cancer Screening After Changes in US Preventive Services Task Force Guidelines With Increased Screening Options.
Benson M; Johannes A; Weiss JM; Lucey M; Pier J; Pfau P
WMJ; 2021 Jul; 120(2):127-130. PubMed ID: 34255952
[TBL] [Abstract][Full Text] [Related]
56. Colon Cancer Screening - Is It Time Yet?
Bhurgri H; Samiullah S
J Coll Physicians Surg Pak; 2017 Jun; 27(6):327-328. PubMed ID: 28689518
[TBL] [Abstract][Full Text] [Related]
57. Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors.
Gini A; Meester RGS; Keshavarz H; Oeffinger KC; Ahmed S; Hodgson DC; Lansdorp-Vogelaar I
J Natl Cancer Inst; 2019 Nov; 111(11):1161-1169. PubMed ID: 30980665
[TBL] [Abstract][Full Text] [Related]
58. Optimising colorectal cancer screening in Shanghai, China: a modelling study.
Cenin D; Li P; Wang J; de Jonge L; Yan B; Tao S; Lansdorp-Vogelaar I
BMJ Open; 2022 May; 12(5):e048156. PubMed ID: 35577474
[TBL] [Abstract][Full Text] [Related]
59. PPV and Detection Rate of mt-sDNA Testing, FIT, and CT Colonography for Advanced Neoplasia: A Hierarchic Bayesian Meta-Analysis of the Noninvasive Colorectal Screening Tests.
Pickhardt PJ; Correale L; Hassan C
AJR Am J Roentgenol; 2021 Oct; 217(4):817-830. PubMed ID: 33703913
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
